Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Prostatic Neoplasms 1Mesothelioma, Malignant 1Kidney Neoplasms 1

Interventions

Cisplatin 15Pemetrexed 12pembrolizumab 9Carboplatin 8Nivolumab 7Platinum 6Cyclophosphamide 6Ipilimumab 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 3atezolizumab 3Radiotherapy, Intensity-Modulated 3Interleukin-2 3Gemcitabine 3tremelimumab 2durvalumab 2aldesleukin 2Radiotherapy 2Radiation 2Photochemotherapy 2Pharmaceutical Preparations 2Methotrexate 2Drug Therapy 2Chemotherapy, Adjuvant 2Cerebral Decortication 2nintedanib 1methoxyamine 1decitabine and cedazuridine drug combination 1cemiplimab 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Surgery, Computer-Assisted × 1 year × Clear all
NCT03760575 2025-12-04

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Abramson Cancer Center at Penn Medicine

Phase 1 Recruiting
20 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡